pe anti mouse cxcr2  (R&D Systems)

Journal: bioRxiv

Article Title: Autocrine CXCL1-CXCR2 Signaling Mediates Leptomeningeal Resistance to Radiation Therapy

doi: 10.1101/2025.02.20.639389

Figure Lengend Snippet: (A) Histogram of immune cell types present within the LM microenvironment at 1 week after inoculation of LLC-LeptoM compared to naïve controls (received i/cist injection of PBS) quantified by flow cytometry. Data represent mean ± SEM. t -test. n = 6. ns = not significant. Neut = neutrophils; NK = natural killer cells; DC = dendritic cells; Mono = monocytes; Mac = macrophages. (B) Flow cytometric analysis of immune cell types present within the LM microenvironment at 1 week after inoculation of 4T1-LeptoM compared to naïve controls quantified by flow cytometry. Data are presented as percentages and represent mean ± SEM. t -test. n = 5. ns = not significant. (C) Histogram of Cxcr2 expressing immune cells within the LM microenvironment 1 week after inoculation of LLC-LeptoM and naive controls quantified by flow cytometry. Data represent mean ± SEM. n = 6 per each condition. (D) Immune cell Cxcr2 expression within the leptomeningeal microenvironment 1 week after inoculation of 4T1-LeptoM and naive controls as quantified by flow cytometry. Data represent mean ± SEM. n = 5 per each condition. (E) Tumor growth of wildtype (WT) and mice lacking Cxcr2 expression in immune cells (Cxcr2 KO) quantified by BLI. Data represent mean ± SEM. Two-way ANOVA with Bonferroni correction. WT n = 9; Cxcr2 KO n = 4. p = 0.0002. (F) Histogram of Cxcr2 expressing cells in LLC-LeptoM and 4T1-LeptoM cell lines when cells were grown in vitro, as quantified by flow cytometry. LLC-LeptoM: n = 4 independent experiments. 4T1-LeptoM: n = 3 independent experiments. (G) Histogram of Cxcr2 expressing cells in LLC-LeptoM and 4T1-LeptoM cell lines quantified by flow cytometry at different time points after i/cist inoculation of cancer cells. LLC-LeptoM: n = 5; 4T1-LeptoM: n = 5 per time point.

Article Snippet: The following antibodies were used: BUV395 rat anti-mouse CD45 (Clone 30-F11; BD Horizon #564279); brilliant violet 421 anti-mouse/human CD45R/B220 (Clone RA3-6B2; BioLegend #103251); brilliant violet 650 anti-mouse NK-1.1 (Clone PK136; BioLegend #108736); brilliant violet 711 anti-mouse F4/80 (Clone BM8; BioLegend #123147); brilliant violet 785 anti-mouse Ly6G (Clone 1A8; BioLegend #127645); PerCP anti-mouse Ly6C (Clone HK1.4; BioLegend #128027); PE/Cy7 anti-mouse/human CD11b (Clone M1/70; BioLegend #101216); Alexa Fluor 647 anti-mouse CD11c (Clone N418; BioLegend #117314); APC/fire 750 anti-mouse TCR β Chain (Clone H57-597; BioLegend #109246); PE anti-mouse Cxcr2 (R&D Systems #FAB2164P).

Techniques: Injection, Flow Cytometry, Expressing, In Vitro

Journal: bioRxiv

Article Title: Autocrine CXCL1-CXCR2 Signaling Mediates Leptomeningeal Resistance to Radiation Therapy

doi: 10.1101/2025.02.20.639389

Figure Lengend Snippet: (A) Percentage of Cxcr2 expressing (Cxcr2+) LLC-LeptoM cells before (initial) and after i/cist inoculation as quantified by flow cytometry. Initial: n = 4 independent experiments. i/cist: n = 5 per time point. (B) Percentage of Cxcr2+ 4T1-LeptoM cells before (initial) and after i/cist inoculation as quantified by flow cytometry. Initial: n = 4 independent experiments. i/cist: n = 5 per time point. (C) Tumor growth of selected Cxcr2+, Cxcr2 negative (Cxcr2-) and the original heterogeneous (Hetero) LLC-LeptoM cells as quantified by BLI. Data represent mean ± SEM analyzed using two-way ANOVA with Bonferroni correction. Hetero: n = 9; Cxcr2-n = 8; Cxcr2+ n = 8. Hetero vs Cxcr2- p = 0.5433; Hetero vs Cxcr2+ p <0.0001; Cxcr2-vs Cxcr2+. p < 0.0001. (D) Tumor growth of selected Cxcr2+, Cxcr2 negative (Cxcr2-) and the original heterogeneous (Hetero) 4T1-LeptoM cells as quantified by BLI. Data represent mean ± SEM analyzed using two-way ANOVA with Bonferroni correction. Hetero: n = 9; Cxcr2-n = 8; Cxcr2+ n = 8. Hetero vs Cxcr2- p = 0.5466; Hetero vs Cxcr2+ p <0.0001; Cxcr2-vs Cxcr2+. p < 0.0001. (E) Principal component analysis (PCA) plot showing distinct transcriptional clustering of Cxcr2- and Cxcr2+ cell populations in both LLC-LeptoM and 4T1-LeptoM cell lines. (F) Left: Histogram of differentially expressed genes (DEGs) between Cxcr2- and Cxcr2+ cells in LLC-LeptoM and 4T1-LeptoM cell lines. Right: Venn diagram illustrating unique and shared DEGs between LeptoM cells lines. (G) Gene ontology analysis of top 20 significantly enriched pathways in Cxcr2+ cells of LLC-LeptoM (left) and 4T1-LeptoM (right).

Article Snippet: The following antibodies were used: BUV395 rat anti-mouse CD45 (Clone 30-F11; BD Horizon #564279); brilliant violet 421 anti-mouse/human CD45R/B220 (Clone RA3-6B2; BioLegend #103251); brilliant violet 650 anti-mouse NK-1.1 (Clone PK136; BioLegend #108736); brilliant violet 711 anti-mouse F4/80 (Clone BM8; BioLegend #123147); brilliant violet 785 anti-mouse Ly6G (Clone 1A8; BioLegend #127645); PerCP anti-mouse Ly6C (Clone HK1.4; BioLegend #128027); PE/Cy7 anti-mouse/human CD11b (Clone M1/70; BioLegend #101216); Alexa Fluor 647 anti-mouse CD11c (Clone N418; BioLegend #117314); APC/fire 750 anti-mouse TCR β Chain (Clone H57-597; BioLegend #109246); PE anti-mouse Cxcr2 (R&D Systems #FAB2164P).

Techniques: Expressing, Flow Cytometry

Journal: bioRxiv

Article Title: Autocrine CXCL1-CXCR2 Signaling Mediates Leptomeningeal Resistance to Radiation Therapy

doi: 10.1101/2025.02.20.639389

Figure Lengend Snippet: (A) Experimental treatment scheme illustrating i/cist treatment with Cxcr2 inhibitor SB265610 (SB) or vehicle (Veh) in LLC-LeptoM model. Treatments were co-injected with cancer cells and maintained for 2 weeks. (B) Left: Tumor growth as quantified by BLI. Right: Representative BLI images 3 weeks after inoculation of cancer cells. Data represent mean ± SEM. Two-way ANOVA with Bonferroni correction. Veh n = 8; SB n = 8. p < 0.0001. (C) Kaplan-Meier survival curve of mice in ( B ). p < 0.0001. (D) Scheme showing the paradigm of late treatment with Cxcr2 inhibitor SB with or without CSI (10 Gy delivered as 2 Gy × 5 fractions). Treatments initiated one week after inoculation of cancer cells and continued for 2 weeks. (E) Left: Tumor growth quantified by BLI. Right: Representative BLI images 3 weeks after inoculation of cancer cells. Data represent mean ± SEM. Two-way ANOVA with Bonferroni correction. SH + Veh n = 9; CSI + Veh n = 9; SH + SB n = 9; CSI + SB n = 8. SH + Veh vs CSI + Veh p = 0.0371; SH + Veh vs SH + SB p = 0.0237; SH + Veh vs CSI + SB p = 0.0143. (F) Kaplan-Meier survival curve of mice in ( E ). SH + Veh vs CSI + Veh p = 0. 4338; SH + Veh vs SH + SB p = 0.7390; SH + Veh vs CSI + SB p = 0.0050. (G) Kaplan-Meier curve comparing the overall survival of LM patients stratified based on the percentage of CXCR2 expression in cancer cells (EpCAM+/CXCR2+) in CSF prior to pCSI. CXCR2 low (less than 1%) n = 10; CXCR2 high (more than 1%) n = 8. p = 0.0353. mo = month.

Article Snippet: The following antibodies were used: BUV395 rat anti-mouse CD45 (Clone 30-F11; BD Horizon #564279); brilliant violet 421 anti-mouse/human CD45R/B220 (Clone RA3-6B2; BioLegend #103251); brilliant violet 650 anti-mouse NK-1.1 (Clone PK136; BioLegend #108736); brilliant violet 711 anti-mouse F4/80 (Clone BM8; BioLegend #123147); brilliant violet 785 anti-mouse Ly6G (Clone 1A8; BioLegend #127645); PerCP anti-mouse Ly6C (Clone HK1.4; BioLegend #128027); PE/Cy7 anti-mouse/human CD11b (Clone M1/70; BioLegend #101216); Alexa Fluor 647 anti-mouse CD11c (Clone N418; BioLegend #117314); APC/fire 750 anti-mouse TCR β Chain (Clone H57-597; BioLegend #109246); PE anti-mouse Cxcr2 (R&D Systems #FAB2164P).

Techniques: Injection, Expressing

Journal: Antioxidants

Article Title: The C-X-C Motif Chemokine Ligand 5, Which Exerts an Antioxidant Role by Inducing HO-1 Expression, Is C-X-C Motif Chemokine Receptor 2-Dependent in Human Prostate Stroma and Cancer Cells

doi: 10.3390/antiox13121489

Figure Lengend Snippet: Modulation of CXCL5 in the cell proliferation and invasion of prostate cancer cells. ( A ) CXCL5 mRNA levels of prostate cells were determined by RT-qPCR. Data are presented as the ΔCT relative to β-actin. The cell immunofluorescent staining of CXCR2 protein in LNCaP ( B ) and PC-3 ( C ) cells was determined by flow cytometry. Data from quantitative analysis represented the percentage of CXCR2-positive cells. ( D ) CXCL5 levels in the supernatant from PC_shCOL and PC_shCXCL5 cells were assessed by ELISA. ( E ) The mRNA levels (±SE, n = 3) of CXCL5 and HO-1 of PC_shCOL cells relative to PC_shCXCL5 cells. ( F ) Reporter activity (±SE, n = 6) of HO-1 reporter vector after co-transfected with various dosages of CXCL5 expression vectors. ( G ) The protein levels of the CXCR2, CXCL5, and HO-1 of mock-transducted PC-3 (PC_shCOL) and CXCL5 knockdown PC-3 (PC_shCXCL5) cells were examined by immunoblot assays. Quantitative analysis (±SE, n = 3) was presented as a relative density of proteins/β-actin. ( H ) The abilities of cellular proliferation in PC_shCOL and PC_shCXCL5 cells were measured by flow cytometry using a Ki67 flow cytometry kit (±SE, n = 3). ( I ) The protein levels of EMT markers (E-cadherin, N-cadherin, Snail, Slug, and Vimentin) in PC_shCOL and PC_shCXCL5 cells were determined by immunoblot assays and quantitative analysis (±SE, n = 3). ( J ) The cellular invasion ability was determined by in vitro Matrigel invasion assays. Data are presented as the mean percentage (±SE; n = 3) in relation to the PC_shCOL cells. ( K ) The cell numbers for neutrophil trans-membrane migration induced by supernatant from PC_shCOL and PC_shCXCL5 cells (±SE, n = 3). * p < 0.05, ** p < 0.01.

Article Snippet: Cells were washed with PBS containing 1% bovine serum albumin (BSA) and incubated with PE-conjugated mouse anti-human CXCR2 antibody (FAB331P, R&D Systems Inc., Shanghai, China) or PE-conjugated mouse IgG2a control antibody (IC003P, R&D Systems Inc.) for 1 h at room temperature.

Techniques: Quantitative RT-PCR, Staining, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Activity Assay, Plasmid Preparation, Transfection, Expressing, Knockdown, Western Blot, In Vitro, Membrane, Migration

Journal: Antioxidants

Article Title: The C-X-C Motif Chemokine Ligand 5, Which Exerts an Antioxidant Role by Inducing HO-1 Expression, Is C-X-C Motif Chemokine Receptor 2-Dependent in Human Prostate Stroma and Cancer Cells

doi: 10.3390/antiox13121489

Figure Lengend Snippet: Modulation of CXCL5 and SB225002 in endogenous and H 2 O 2 -induced ROS in prostate cancer PC-3 cells. ( A ) ROS levels and quantitative data from PC_shCOL and PC_shCXCL5 cells after treatment with or without H 2 O 2 , as measured by flow cytometry. ( B ) The levels of the CXCR2, HO-1, and CXCL5 proteins after treatment with various concentrations of SB225002, as indicated, as examined by immunoblotting assays. Quantitative data are presented as the intensity of the protein bands of the target proteins/β-actin relative to the vehicle-treated group. ( C ) ROS levels and quantitative data from PC3 cells after treatment with various concentrations of SB225002 and with/without H 2 O 2 , as measured by flow cytometry. ** p < 0.01.

Article Snippet: Cells were washed with PBS containing 1% bovine serum albumin (BSA) and incubated with PE-conjugated mouse anti-human CXCR2 antibody (FAB331P, R&D Systems Inc., Shanghai, China) or PE-conjugated mouse IgG2a control antibody (IC003P, R&D Systems Inc.) for 1 h at room temperature.

Techniques: Flow Cytometry, Western Blot

Journal: Antioxidants

Article Title: The C-X-C Motif Chemokine Ligand 5, Which Exerts an Antioxidant Role by Inducing HO-1 Expression, Is C-X-C Motif Chemokine Receptor 2-Dependent in Human Prostate Stroma and Cancer Cells

doi: 10.3390/antiox13121489

Figure Lengend Snippet: Modulation of CXCL5 via CXC2R in endogenous and H 2 O 2 -induced ROS in prostate cancer LNCaP cells. ( A ) The protein levels of CXCR2, PSA, and HO-1 of LN-DNA, LN-CXCL5, and SB225002-treated LN-CXCL5 cells were examined by immunoblot assays. Quantitative analysis (±SE, n = 3) is presented as the relative density of target proteins/β-actin. ( B ) Reporter activity (±SE, n = 6) of the PSA reporter vector after co-transfected with various doses of CXCL5 expression vectors. ( C ) PSA levels (±SE, n = 6) in the supernatant of LN-DNA, LN-CXCL5, and LN-CXC5 treated with CXCL5 antibody or CXCR2 antibody, as assessed by ELISA. Data are presented as PSA secretion in relation to the LN-DNA group. ( D ) ROS levels and quantitative data (±SE, n = 3) of LN-DNA and LN-CXCL5 cells after treatment with or without H 2 O 2 and SB225002, as measured by flow cytometry. ( E ) HO-1 protein levels when LN-CXCL5 cells were transiently knocked down as to the HO-1 gene by immunoblot assays and quantitative analysis (±SE, n = 3). ( F ) ROS levels and quantitative data (±SE, n = 3) from LN-DNA, LN-CXCL5, and HO-1-knockdown LN-CXCL5 cells after treatment with/without H 2 O 2 , as measured by flow cytometry. ** p < 0.01. N.S., no significant difference.

Article Snippet: Cells were washed with PBS containing 1% bovine serum albumin (BSA) and incubated with PE-conjugated mouse anti-human CXCR2 antibody (FAB331P, R&D Systems Inc., Shanghai, China) or PE-conjugated mouse IgG2a control antibody (IC003P, R&D Systems Inc.) for 1 h at room temperature.

Techniques: Western Blot, Activity Assay, Plasmid Preparation, Transfection, Expressing, Enzyme-linked Immunosorbent Assay, Flow Cytometry, Knockdown

Journal: Antioxidants

Article Title: The C-X-C Motif Chemokine Ligand 5, Which Exerts an Antioxidant Role by Inducing HO-1 Expression, Is C-X-C Motif Chemokine Receptor 2-Dependent in Human Prostate Stroma and Cancer Cells

doi: 10.3390/antiox13121489

Figure Lengend Snippet: Modulation of CXCL5 in cell contraction and migration in prostate stroma myofibroblast WPMY-1 cells. ( A ) Cell immunofluorescent staining of the CXCR2 protein in WPMY-1 cells was determined by flow cytometry. The data from the quantitative analysis represents the percentage of CXCR2-positive cells. ( B ) Protein levels of Fibronectin, α-SMA, HO-1, CXCL5, and β-actin in WPMY-1-DNA and WPMY-1-CXCL5 cells, as determined by immunoblot assays and quantitative analysis (±SE, n = 3). ( C ) Cell contraction of mock-transfected WPMY-1 (WPMY-1-DNA) and CXCL5-overexpressed WPMY-1 (WPMY-1-CXCL5) cells, as measured by collagen contraction assays. Data are presented as the mean percentage (±SE; n = 3) of WPMY-1-CXCL5 cells in relation to WPMY-1-DNA cells. ( D ) Cell contraction of WPMY-1 cells when treated with the supernatant from the LN-DNA, LN-CXCL5, or LN-CXCL5 with SB225002. Data are presented as the mean percentage (±SE; n = 3) in relation to the supernatant from LN-DNA-treated WPMY-1 cells. ( E ) Migration capabilities in WPMY1 cells treated with conditioned media of LN-DNA, LN-CXCL5, or LN-CXCL5 with SB225002. The white line indicates the average of the leading edges of cells and the size of the wound area. Data are presented as the mean percentage (±SE; n = 3) in relation to the supernatant from LN-DNA-treated WPMY-1 cells. * p < 0.05, ** p < 0.01.

Article Snippet: Cells were washed with PBS containing 1% bovine serum albumin (BSA) and incubated with PE-conjugated mouse anti-human CXCR2 antibody (FAB331P, R&D Systems Inc., Shanghai, China) or PE-conjugated mouse IgG2a control antibody (IC003P, R&D Systems Inc.) for 1 h at room temperature.

Techniques: Migration, Staining, Flow Cytometry, Western Blot, Transfection

Journal: Antioxidants

Article Title: The C-X-C Motif Chemokine Ligand 5, Which Exerts an Antioxidant Role by Inducing HO-1 Expression, Is C-X-C Motif Chemokine Receptor 2-Dependent in Human Prostate Stroma and Cancer Cells

doi: 10.3390/antiox13121489

Figure Lengend Snippet: Modulation of CXCL5 and SB225002 in endogenous and H 2 O 2 -induced ROS in prostate stroma myofibroblast WPMY-1 cells. ( A ) The protein levels of α-SMA, CXCR2, and HO-1 of WPMY-1 cells after treatment with the conditioned media of the LN-DNA, LN-CXCL5, or LN-CXCL5 with SB225002, as examined by immunoblot assays. Quantitative analysis (±SE, n = 3) is presented as the relative density of target proteins/β-actin. ( B ) ROS levels and quantitative data for WPMY-1 cells after treatment with the conditioned media of the LN-DNA, LN-CXCL5, or LN-CXCL5 with SB225002, and with/without H2O2, as measured by flow cytometry. ( C ) ROS levels and quantitative data from WPMY-1-DNA, WPMY-1-CXCL5, and SB225002-treated WPMY-1-CXCL5 cells, after treatment with or without H 2 O 2 , as measured by flow cytometry. ( D ) ROS levels and quantitative data for WPMY-1 cells after treatment with 2 μM SB225002 and with/without H 2 O 2 , as measured by flow cytometry. * p < 0.05, ** p < 0.01.

Article Snippet: Cells were washed with PBS containing 1% bovine serum albumin (BSA) and incubated with PE-conjugated mouse anti-human CXCR2 antibody (FAB331P, R&D Systems Inc., Shanghai, China) or PE-conjugated mouse IgG2a control antibody (IC003P, R&D Systems Inc.) for 1 h at room temperature.

Techniques: Western Blot, Flow Cytometry

Journal: bioRxiv

Article Title: Prostaglandin E 2 production is required for phagocyte CXCR2-mediated skin host defense in obese and hyperglycemic mice

doi: 10.1101/2022.10.02.510554

Figure Lengend Snippet: A) Levels of IL-1, CXCL1, CXCL2, and CXCL5 in skin biopsy homogenates collected at day 3 post infection in LFD and HFD mice treated with or without misoprostol and measured using a bead array multiplex. Absolute cell numbers of B) Ly6C+CD11b+, C) Ly6G+CD11b+, D) F4/80+CD11b+, E) Ly6C+CD11b+ CXCR2+, F) Ly6G+CD11b+ CXCR2+ and F4/80+CD11b+ CXCR2+ in the infected skin of mice treated as in A as detected by FACS. Data are mean ± SEM of 5-10 mice from at least 2 independent experiments. *p < 0.05 vs. LFD mice. #p<0.05 vs. HFD mice treated with vehicle control.

Article Snippet: The following antibodies were utilized: F4/80-FITC (Biolegend; catalog 123107; clone BM8), CXCR2-PE (R&D; catalog FAB2164P), Ly6G-PerCP/Cy5.5 (Biolegend; catalog 127616; clone 1A8) Ly6C-AF647 (Biolegend; catalog 128010; clone HK14), CD11b-PE/Cy7 (Biolegend; catalog 101216; clone M1/70).

Techniques: Infection, Multiplex Assay

Journal: bioRxiv

Article Title: Prostaglandin E 2 production is required for phagocyte CXCR2-mediated skin host defense in obese and hyperglycemic mice

doi: 10.1101/2022.10.02.510554

Figure Lengend Snippet: A) cAMP levels in the infected skin of LFD and HFD mice treated with or without topical misoprostol (0.03%) or vehicle control at day 3 post-infection as measured by EIA. B) Top panel: H&E stained sections of the skin of mice treated as in A at day 3 post-infection. Bottom panel: MALDI imaging for cAMP and adenosine monophosphate (AMP) determined by imaging mass spectrometry as described in the Methods. Data are representative of at least 5 individual mice/group. C) Representative images of bioluminescent MRSA in LFD and HFD mice at day 3 post-infection using planar bioluminescent imaging. Top . LFD and HFD mice treated with or without misoprostol plus the EP3 antagonist L-798,106 as described in Methods. Bottom : LFD and HFD WT and EP3-/- mice treated with or without misoprostol twice daily for 3 days. Numbers below are quantification of Total flux from mice treated as described above at day 3 post-infection using the IVIS Spectrum D) Bacterial burden as measured by CFU from skin biopsy homogenates from LFD and HFD WT and EP3-/- mice treated with or without misoprostol at day 3 post infection (E and F) . Absolute cell numbers of E) Ly6G+CD11b+ CXCR2+, E) Ly6C+CD11b+ CXCR2+ in the infected skin WT and EP3KO LFD and HFD mice treated with or without misoprostol at day 3 post-infection as detected by FACS. Data represent the mean ±SEM from 4-5 mice from 2-3 independent experiments. *p<0.05 vs. LFD. #p<0.05 vs. HFD. &p<0.05 vs. HFD+Miso.

Article Snippet: The following antibodies were utilized: F4/80-FITC (Biolegend; catalog 123107; clone BM8), CXCR2-PE (R&D; catalog FAB2164P), Ly6G-PerCP/Cy5.5 (Biolegend; catalog 127616; clone 1A8) Ly6C-AF647 (Biolegend; catalog 128010; clone HK14), CD11b-PE/Cy7 (Biolegend; catalog 101216; clone M1/70).

Techniques: Infection, Staining, Imaging, Mass Spectrometry

Journal: bioRxiv

Article Title: Prostaglandin E 2 production is required for phagocyte CXCR2-mediated skin host defense in obese and hyperglycemic mice

doi: 10.1101/2022.10.02.510554

Figure Lengend Snippet: Lean and Obese mice were treated with with topical misoprostol and/or the CXCR2+ antagonist (Navarixin) (5mg/kg) together or individually at day 1 and day 3 post-infection. A) Total number of Ly6G+CD11b+CXCR2+ neutrophils in the skin of lean and obese mice treated as in A at day 3 postinfection as measured by flow cytometry. B) Total number of Ly6C+CD11b+CXCR2+ monocytes in the skin of lean and obese mice infected and treated as above at day 3 post-infection as measured by flow cytometry. C) Representative images of bioluminescent MRSA in the skin of LFD and HFD animals treated with misoprostol or a CXCR2+ antagonist (Navarixin) (5mg/kg) together or individually at day 1 and day 3 post-infection using the IVIS Spectrum. D) Bacterial burden as measured by CFU from skin biopsy homogenates from mice treated as above at day 3 post-infection. E) Bacterial load in the skin of lean and obese LysMCre and CXCR2 Δmyel treated with or without misoprostol twice daily for 3 days determined by CFU Data represent the mean ± SEM from 3-5 mice from 2-3 independent experiments. *p<0.05 vs. LFD. #p<0.05 vs. HFD. &p<0.05 vs. HFD+Miso (One-way ANOVA followed by Bonferroni multiple comparison test).

Article Snippet: The following antibodies were utilized: F4/80-FITC (Biolegend; catalog 123107; clone BM8), CXCR2-PE (R&D; catalog FAB2164P), Ly6G-PerCP/Cy5.5 (Biolegend; catalog 127616; clone 1A8) Ly6C-AF647 (Biolegend; catalog 128010; clone HK14), CD11b-PE/Cy7 (Biolegend; catalog 101216; clone M1/70).

Techniques: Infection, Flow Cytometry

Journal: eLife

Article Title: Chronic ethanol consumption compromises neutrophil function in acute pulmonary Aspergillus fumigatus infection

doi: 10.7554/eLife.58855

Figure Lengend Snippet:

Article Snippet: Antibody , anti-CXCR2-PE (Rat monoclonal) , R and D Systems , Cat# FAB2164P , FACS (1:10).

Techniques: Isolation, Recombinant, Chemotaxis Assay, Purification, Blocking Assay, Enzyme-linked Immunosorbent Assay, Software